Cargando…

Drug combination sensitivity scoring facilitates the discovery of synergistic and efficacious drug combinations in cancer

High-throughput drug screening has facilitated the discovery of drug combinations in cancer. Many existing studies adopted a full matrix design, aiming for the characterization of drug pair effects for cancer cells. However, the full matrix design may be suboptimal as it requires a drug pair to be c...

Descripción completa

Detalles Bibliográficos
Autores principales: Malyutina, Alina, Majumder, Muntasir Mamun, Wang, Wenyu, Pessia, Alberto, Heckman, Caroline A., Tang, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6544320/
https://www.ncbi.nlm.nih.gov/pubmed/31107860
http://dx.doi.org/10.1371/journal.pcbi.1006752
_version_ 1783423239755661312
author Malyutina, Alina
Majumder, Muntasir Mamun
Wang, Wenyu
Pessia, Alberto
Heckman, Caroline A.
Tang, Jing
author_facet Malyutina, Alina
Majumder, Muntasir Mamun
Wang, Wenyu
Pessia, Alberto
Heckman, Caroline A.
Tang, Jing
author_sort Malyutina, Alina
collection PubMed
description High-throughput drug screening has facilitated the discovery of drug combinations in cancer. Many existing studies adopted a full matrix design, aiming for the characterization of drug pair effects for cancer cells. However, the full matrix design may be suboptimal as it requires a drug pair to be combined at multiple concentrations in a full factorial manner. Furthermore, many of the computational tools assess only the synergy but not the sensitivity of drug combinations, which might lead to false positive discoveries. We proposed a novel cross design to enable a more cost-effective and simultaneous testing of drug combination sensitivity and synergy. We developed a drug combination sensitivity score (CSS) to determine the sensitivity of a drug pair, and showed that the CSS is highly reproducible between the replicates and thus supported its usage as a robust metric. We further showed that CSS can be predicted using machine learning approaches which determined the top pharmaco-features to cluster cancer cell lines based on their drug combination sensitivity profiles. To assess the degree of drug interactions using the cross design, we developed an S synergy score based on the difference between the drug combination and the single drug dose-response curves. We showed that the S score is able to detect true synergistic and antagonistic drug combinations at an accuracy level comparable to that using the full matrix design. Taken together, we showed that the cross design coupled with the CSS sensitivity and S synergy scoring methods may provide a robust and accurate characterization of both drug combination sensitivity and synergy levels, with minimal experimental materials required. Our experimental-computational approach could be utilized as an efficient pipeline for improving the discovery rate in high-throughput drug combination screening, particularly for primary patient samples which are difficult to obtain.
format Online
Article
Text
id pubmed-6544320
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-65443202019-06-17 Drug combination sensitivity scoring facilitates the discovery of synergistic and efficacious drug combinations in cancer Malyutina, Alina Majumder, Muntasir Mamun Wang, Wenyu Pessia, Alberto Heckman, Caroline A. Tang, Jing PLoS Comput Biol Research Article High-throughput drug screening has facilitated the discovery of drug combinations in cancer. Many existing studies adopted a full matrix design, aiming for the characterization of drug pair effects for cancer cells. However, the full matrix design may be suboptimal as it requires a drug pair to be combined at multiple concentrations in a full factorial manner. Furthermore, many of the computational tools assess only the synergy but not the sensitivity of drug combinations, which might lead to false positive discoveries. We proposed a novel cross design to enable a more cost-effective and simultaneous testing of drug combination sensitivity and synergy. We developed a drug combination sensitivity score (CSS) to determine the sensitivity of a drug pair, and showed that the CSS is highly reproducible between the replicates and thus supported its usage as a robust metric. We further showed that CSS can be predicted using machine learning approaches which determined the top pharmaco-features to cluster cancer cell lines based on their drug combination sensitivity profiles. To assess the degree of drug interactions using the cross design, we developed an S synergy score based on the difference between the drug combination and the single drug dose-response curves. We showed that the S score is able to detect true synergistic and antagonistic drug combinations at an accuracy level comparable to that using the full matrix design. Taken together, we showed that the cross design coupled with the CSS sensitivity and S synergy scoring methods may provide a robust and accurate characterization of both drug combination sensitivity and synergy levels, with minimal experimental materials required. Our experimental-computational approach could be utilized as an efficient pipeline for improving the discovery rate in high-throughput drug combination screening, particularly for primary patient samples which are difficult to obtain. Public Library of Science 2019-05-20 /pmc/articles/PMC6544320/ /pubmed/31107860 http://dx.doi.org/10.1371/journal.pcbi.1006752 Text en © 2019 Malyutina et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Malyutina, Alina
Majumder, Muntasir Mamun
Wang, Wenyu
Pessia, Alberto
Heckman, Caroline A.
Tang, Jing
Drug combination sensitivity scoring facilitates the discovery of synergistic and efficacious drug combinations in cancer
title Drug combination sensitivity scoring facilitates the discovery of synergistic and efficacious drug combinations in cancer
title_full Drug combination sensitivity scoring facilitates the discovery of synergistic and efficacious drug combinations in cancer
title_fullStr Drug combination sensitivity scoring facilitates the discovery of synergistic and efficacious drug combinations in cancer
title_full_unstemmed Drug combination sensitivity scoring facilitates the discovery of synergistic and efficacious drug combinations in cancer
title_short Drug combination sensitivity scoring facilitates the discovery of synergistic and efficacious drug combinations in cancer
title_sort drug combination sensitivity scoring facilitates the discovery of synergistic and efficacious drug combinations in cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6544320/
https://www.ncbi.nlm.nih.gov/pubmed/31107860
http://dx.doi.org/10.1371/journal.pcbi.1006752
work_keys_str_mv AT malyutinaalina drugcombinationsensitivityscoringfacilitatesthediscoveryofsynergisticandefficaciousdrugcombinationsincancer
AT majumdermuntasirmamun drugcombinationsensitivityscoringfacilitatesthediscoveryofsynergisticandefficaciousdrugcombinationsincancer
AT wangwenyu drugcombinationsensitivityscoringfacilitatesthediscoveryofsynergisticandefficaciousdrugcombinationsincancer
AT pessiaalberto drugcombinationsensitivityscoringfacilitatesthediscoveryofsynergisticandefficaciousdrugcombinationsincancer
AT heckmancarolinea drugcombinationsensitivityscoringfacilitatesthediscoveryofsynergisticandefficaciousdrugcombinationsincancer
AT tangjing drugcombinationsensitivityscoringfacilitatesthediscoveryofsynergisticandefficaciousdrugcombinationsincancer